<DOC>
	<DOCNO>NCT00371761</DOCNO>
	<brief_summary>This open label , randomize , comparative , multi-center study . Subjects screen within 2 week prior study entry establish eligibility . Subjects meet selection criterion randomly assign 1:1 ( 1 ) once-a-week , subcutaneous Pegylated interferon alfa-2b ( PegIntron ) ( 1.5 mcg/kg body weight ) ( 2 ) oral adefovir 10 mg daily . The treatment phase 24 week PegIntron 48 week adefovir . All subject complete assigned treatment phase follow additional 48 week PegIntron 24 week adefovir observation phase . The primary objective establish efficacy profile PegIntron . Secondary objective compare efficacy profile PegIntron adefovir , compare efficacy PegIntron lamivudine-naïve lamivudine-experienced subject , establish safety profile PegIntron treat patient hepatitis B e antigen ( HBeAg ) -positive chronic hepatitis B .</brief_summary>
	<brief_title>PegIntron Versus Adefovir Treatment Chronic Hepatitis B ( CHB ) e Antigen Positive Patients Taiwan ( P04498/MK-4031-278 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Adult male female , 18 70 year age . Documented positive serum hepatitis B surface antigen ( HBsAg ) minimum 6 month prior randomization . Hepatitis B virus ( HBV ) replication hepatitis document : Serum HBV DNA ( Hepatitis B Virus Deoxyribonucleic acid ) &gt; = 10^5 copies/mL within 3 month prior entry Positive serum hepatitis B e antigen ( HBeAg ) within 3 month prior entry Documented presence ALT ( Alanine Aminotransferase ) twice ( 1 month apart ) within 3 month prior entry ( 2 10 fold upper normal level ) Liver biopsy finding show evidence chronic hepatitis without liver cirrhosis , document acceptable antiHBV treatment within 1 year prior randomization Naïve expose lamivudine ( 3 month treatmentfree interval prior randomization ) Adequate renal function ( creatinine within normal upper limit ) . Compensated liver disease certain minimum hematological serum biochemical criterion . Thyroid stimulate hormone ( TSH ) free T4 within normal range . Negative antibody hepatitis C hepatitis D. Negative antibody human immunodeficiency virus . Negative evidence hepatocellular carcinoma alfafetoprotein ultrasound within 1 month prior randomization . Women pregnant nursing . Prior treatment hepatitis interferon adefovir , investigational antivirus agent . Prior treatment hepatitis immunomodulatory drug within 2 year prior randomization . Suspected hypersensitivity interferon adefovir . Liver cirrhosis . History severe psychiatric disease , especially depression . Concurrent malignancy ( include hepatocellular carcinoma ) . Unstable significant cardiovascular disease . Prolonged exposure know hepatotoxin . History thyroid disease poorly control prescribed medication . Poorly control diabetes mellitus . Have suspect confirm significant hepatic disease etiology HBV . Severe renal disease myeloid dysfunction . History organ transplantation cornea hair transplant . Any medical condition require chronic systemic administration steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis B virus</keyword>
	<keyword>Pegylated interferon alfa-2b ( PegIntron )</keyword>
</DOC>